Compare Cassava Sciences Inc (FLNA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Okta, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Okta, Inc. trades at $224.61 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 977.2× Cassava Sciences Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Okta, Inc. for 44 Days on average.
| FLNA | OKTA | |
|---|---|---|
Market Cap | $39.40M | $38.50B |
Volume | 759,018 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $4.64 | $220.21 |
52-Week Low | $0.68 | $62.93 |
Typical Hold Time | 37 Days | 44 Days |
Enterprise Value | -$43.28M | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
OKTA trades at $218.00, down slightly by 0.31% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported a net income of $28 million in 2025, marking a significant turnaround from previous losses, while revenue grew to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
Outlook remains positive with robust analyst support (73.58% buy ratings) and a consensus price target of $201.30, though high valuation ratios and overbought RSI readings pose near-term risks. Long-term growth is supported by identity management demand and AI positioning, but competition and execution challenges are key investor considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
